GSK announces EMA accepted for review MAA for depemokimab

EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK announces EMA accepted for review the MAA for depemokimab
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications for depemokimab have been accepted for review by the China National Medical (TASE:PMCN) Products Administration and submitted to the Japanese Ministry of Health,
GSK says asthma and nasal polyps therapy under EU review
GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, for the treatment of asthma and nasal polyps.
GSK rises Monday, outperforms market
GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...
US Weekly on MSN10h
Sheryl Lee Ralph Is Ready to Reunite With Denzel Washington for an ‘Adult Rom-Com’ (Exclusive)
Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...
GSK Pharma put volume heavy and directionally bearish
Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...
Technology is enabling more precise treatments for cancer patients
The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.
pharmaphorum3d
GSK backs £50m Oxford University cancer vaccine programme
The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...
GSK rises Wednesday, outperforms market
Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...
UBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...